Download PDF
Semin Thromb Hemost 2016; 42(06): 662-670
DOI: 10.1055/s-0036-1571337
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination

Hazem Elewa
1   Department of Clinical Pharmacy and Practice, College of Pharmacy, Qatar University, Doha, Qatar
,
Dina Ahmed
2   Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
,
Geoffrey D. Barnes
3   Frankel Cardiovascular Center and Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
28 May 2016 (online)

   Permissions and Reprints

Abstract

Patients with atrial fibrillation (AF) who are treated with oral anticoagulants often have concurrent coronary artery disease. Triple oral antithrombotic therapy (TOAT) is often necessity to prevent stent thrombosis or myocardial infarction associated with percutaneous coronary intervention or acute coronary syndrome in patients with comorbid coronary artery disease and AF. Although the use of TOAT (aspirin, clopidogrel, and warfarin) has excellent efficacy against thrombotic complications, this comes on the expense of increased bleeding risk. This review discusses potential strategies to improve TOAT benefit–risk ratio evidence from the literature. These strategies include: (1) dropping aspirin; (2) reducing the duration of TOAT; (3) switching warfarin to a direct oral anticoagulant (DOAC); (4) the use of DOAC in combination with a single antiplatelet agent; and (5) switching clopidogrel to a novel antiplatelet agent. Although dropping aspirin and reducing TOAT duration should be considered in selected AF patients at low risk of thrombosis, the role of DOACs and novel antiplatelets in TOAT has not been thoroughly studied, and there is limited evidence to support their use currently. Ongoing studies will provide safety and efficacy data to guide clinicians who frequently face the challenge of determining the best TOAT combination for their patients.

Keywords

antithrombotic - antiplatelet - warfarin - atrial fibrillation - acute coronary syndrome
 

  • References

  • 1 Go AS, Hylek EM, Phillips KA , et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285 (18) 2370-2375
    CrossrefPubMedGoogle Scholar
  • 2 Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008; 92 (1) 17-40 , ix i x.
    CrossrefPubMedGoogle Scholar
  • 3 Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86 (5) 516-521
    CrossrefPubMedGoogle Scholar
  • 4 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
    CrossrefPubMedGoogle Scholar
  • 5 Connolly S, Pogue J, Hart R , et al; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367 (9526) 1903-1912
    CrossrefPubMedGoogle Scholar
  • 6 Lip GY, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J 2014; 35 (28) 1844-1855
    CrossrefPubMedGoogle Scholar
  • 7 Skjøth F, Larsen TB, Rasmussen LH, Lip GY. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014; 111 (5) 981-988
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Spinler SA, Shafir V. New oral anticoagulants for atrial fibrillation. Circulation 2012; 126 (1) 133-137
    CrossrefPubMedGoogle Scholar
  • 9 Camm AJ, Lip GYH, De Caterina R , et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33 (21) 2719-2747
    CrossrefPubMedGoogle Scholar
  • 10 You JJ, Singer DE, Howard PA , et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e531S-e575S
    CrossrefPubMedGoogle Scholar
  • 11 Capodanno D, Angiolillo DJ. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv 2014; 7 (1) 113-124
    CrossrefPubMedGoogle Scholar
  • 12 Sørensen R, Gislason G. Triple antithrombotic therapy: risky but sometimes necessary. Rev Esp Cardiol (Engl Ed) 2014; 67 (3) 171-175
    CrossrefPubMedGoogle Scholar
  • 13 Mega J, Carreras ET. Antithrombotic therapy: triple therapy or triple threat?. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 547-552
    PubMedGoogle Scholar
  • 14 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK ; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (7) 494-502
    CrossrefPubMedGoogle Scholar
  • 15 Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12 (1) 30-47
    PubMedGoogle Scholar
  • 16 Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother 2011; 12 (8) 1285-1295
    CrossrefPubMedGoogle Scholar
  • 17 Wallentin L, Becker RC, Budaj A , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
    CrossrefPubMedGoogle Scholar
  • 18 Wiviott SD, Braunwald E, McCabe CH , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
    CrossrefPubMedGoogle Scholar
  • 19 Lip GY, Windecker S, Huber K , et al; Document Reviewers. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35 (45) 3155-3179
    CrossrefPubMedGoogle Scholar
  • 20 O'Gara PT, Kushner FG, Ascheim DD , et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127 (4) e362-e425
    CrossrefPubMedGoogle Scholar
  • 21 Bonaca MP, Bhatt DL, Cohen M , et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372 (19) 1791-1800
    CrossrefPubMedGoogle Scholar
  • 22 Mauri L, Kereiakes DJ, Yeh RW , et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371 (23) 2155-2166
    CrossrefPubMedGoogle Scholar
  • 23 Palmerini T, Benedetto U, Bacchi-Reggiani L , et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015; 385 (9985) 2371-2382
    CrossrefPubMedGoogle Scholar
  • 24 Nieuwlaat R, Capucci A, Camm AJ , et al; European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26 (22) 2422-2434
    CrossrefPubMedGoogle Scholar
  • 25 Nabauer M, Gerth A, Limbourg T , et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11 (4) 423-434
    CrossrefPubMedGoogle Scholar
  • 26 Feit F, Voeltz MD, Attubato MJ , et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 2007; 100 (9) 1364-1369
    CrossrefPubMedGoogle Scholar
  • 27 Karjalainen PP, Porela P, Ylitalo A , et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28 (6) 726-732
    CrossrefPubMedGoogle Scholar
  • 28 Ruiz-Nodar JM, Marín F, Hurtado JA , et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51 (8) 818-825
    CrossrefPubMedGoogle Scholar
  • 29 Sørensen R, Hansen ML, Abildstrom SZ , et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374 (9706) 1967-1974
    CrossrefPubMedGoogle Scholar
  • 30 Dewilde WJM, Oirbans T, Verheugt FWA , et al; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381 (9872) 1107-1115
    CrossrefPubMedGoogle Scholar
  • 31 Hansen ML, Sørensen R, Clausen MT , et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170 (16) 1433-1441
    CrossrefPubMedGoogle Scholar
  • 32 Lamberts M, Olesen JB, Ruwald MH , et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; 126 (10) 1185-1193
    CrossrefPubMedGoogle Scholar
  • 33 Goto K, Nakai K, Shizuta S , et al; CREDO-Kyoto Registry Cohort-2 Investigators. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol 2014; 114 (1) 70-78
    CrossrefPubMedGoogle Scholar
  • 34 Lamberts M, Gislason GH, Lip GYH , et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014; 129 (15) 1577-1585
    CrossrefPubMedGoogle Scholar
  • 35 Lamberts M, Gislason GH, Olesen JB , et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013; 62 (11) 981-989
    CrossrefPubMedGoogle Scholar
  • 36 Rha S-W. Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents. World J Cardiol 2014; 6 (4) 148-153
    CrossrefPubMedGoogle Scholar
  • 37 Elmariah S, Mauri L, Doros G , et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 2015; 385 (9970) 792-798
    CrossrefPubMedGoogle Scholar
  • 38 Fiedler KA, Maeng M, Mehilli J , et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol 2015; 65 (16) 1619-1629
    Google Scholar
  • 39 Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110 (3) 453-460
    CrossrefPubMedGoogle Scholar
  • 40 Lippi G, Favaloro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring?. Semin Thromb Hemost 2014; 40 (7) 756-765
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Alexander JH, Becker RC, Bhatt DL , et al; APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119 (22) 2877-2885
    CrossrefPubMedGoogle Scholar
  • 42 Mega JL, Braunwald E, Wiviott SD , et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (1) 9-19
    CrossrefPubMedGoogle Scholar
  • 43 Oldgren J, Budaj A, Granger CB , et al; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32 (22) 2781-2789
    CrossrefPubMedGoogle Scholar
  • 44 Oldgren J, Wallentin L, Alexander JH , et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013; 34 (22) 1670-1680
    CrossrefPubMedGoogle Scholar
  • 45 Connolly SJ, Ezekowitz MD, Yusuf S , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 46 Dans AL, Connolly SJ, Wallentin L , et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013; 127 (5) 634-640
    CrossrefPubMedGoogle Scholar
  • 47 Alexander JH, Lopes RD, James S , et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365 (8) 699-708
    CrossrefPubMedGoogle Scholar
  • 48 Gibson CM, Mehran R, Bode C , et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 2015; 169 (4) 472-8.e5
    CrossrefPubMedGoogle Scholar
  • 49 Sarafoff N, Martischnig A, Wealer J , et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013; 61 (20) 2060-2066
    CrossrefPubMedGoogle Scholar
  • 50 Savonitto S, Ferri M, Corrada E. Fatal bleedings with prasugrel as part of triple antithrombotic therapy. Rev Esp Cardiol (Engl Ed) 2014; 67 (3) 225-226
    CrossrefPubMedGoogle Scholar
  • 51 January CT, Wann LS, Alpert JS , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64 (21) e1-e76
    CrossrefPubMedGoogle Scholar
  • 52 Huber K, Airaksinen KJ, Cuisset T, Marín F, Rubboli A, Lip GYH. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106 (4) 569-571
    Article in Thieme ConnectPubMedGoogle Scholar